Granules Share Price Target 2022, 2023, 2024, 2025, 2030:- Granules India Limited is a large scale vertically integrated company established in 1991 which manufactures Active Pharmaceutical Ingredient (API), Pharmaceutical Intermediate (PFI) and Finished Dosage (FD). Today, along with analyzing the complete details of the business of Granules, we will also look at the future opportunities of the company’s business, so that we will get a little idea in which direction the company’s performance is likely to go in the coming years.
With the help of this article, we have tried to share all possible aspects related to Granule Shares using technical and fundamental analysis.
Granules Share Price Target 2022
Over the years, the company has built a strong position in “first line of defense” products such as paracetamol, ibuprofen, metformin, methocarbamol and guaifenesin. The company’s vertically integrated product-focused business model has created a leadership position in several generic drugs. It has a strong presence in “first line of defense” products including paracetamol, ibuprofen, guaifenesin, and metformin. It exports almost 60% of its revenue to the USA and Europe.
The price target for Granules shares will be available by the end of the financial year 2022. The initial price of Granules will be around Rs 380. And the second granule target will be Rs 400.
| Year | Granules Share Price Target 2022 |
|---|---|
| First Target 2022 | Rs 380 |
| Second Target 2022 | Rs 400 |
Also read:- Fortis Healthcare Share Price Target 2022, 2023, 2024, 2025, 2030
Granules Share Price Target 2023
Granules India is one of the vertically integrated, fast-growing pharmaceutical manufacturing companies in India. Key customers of the granules include some of the leading generic and branded pharmaceutical companies. Its integrated model for API, PFI, and finished batch production enables it to provide products across the value chain and increases its competitiveness. It has developed into a knowledge-oriented multi-product organization focused on research and development with its own strength in the efficient production of large-volume pharmaceutical products.
Granules stock price target by the end of 2023, The target value of the first share of Granules for the financial year 2023 is estimated to be Rs 460. And the second indicative price of Granule could offer around Rs 480.
| Year | Granules Share Price Target 2023 |
|---|---|
| First Target 2023 | Rs 460 |
| Second Target 2023 | Rs 480 |
Also read:- Firstsource Solutions FSL Share Price Target 2022, 2023, 2024, 2025, 2030
Granules Share Price Target 2024
Granules India (GIL) has received a license from the Medicines Patent Pool (MPP) to manufacture and sell generic versions of Pfizer’s oral treatment nirmatrelvir, which will be co-packaged with ritonavir in the treatment of COVID-19. The licenses cover both active pharmaceutical ingredients (API) and finished products in the form of nirmatrelvir, and ritonavir tablets. Nirmatrelvir is an inhibitor of the SARS-CoV-2 3CL-like protease that prevents polyprotein cleavage of proteins necessary for the replication of the SARS-CoV-2 genome. The product will be manufactured at Granules manufacturing facilities in India which are approved by global regulatory authorities including USFDA. The license received by GIL will enable the company to market the product in India and 94 other countries worldwide.
At this moment, we are trying to predict the stock price of two granules that will be available in 2024. The first price target of the granules is Rs 550. And the second pellet price target could cross Rs 570.
| Year | Granules Share Price Target 2024 |
|---|---|
| First Target 2024 | Rs 550 |
| Second Target 2024 | Rs 570 |
Also read:- Aurobindo Pharma Share Price Target 2022, 2023, 2024, 2025, 2030
Granules Share Price Target 2025
Granules India, a wholly owned foreign subsidiary of Granules Pharmaceuticals, Inc. (GPI), has received approval from the US Food & Drug Administration (USFDA) of an abbreviated new drug application (ANDA) for bupropion hydrochloride extended-release tablets USP (XL), 150 mg and 300 mg. It is bioequivalent to the reference listed drug Wellbutrin XL Extended-Release Tablets, 150 mg and 300 mg, from Bausch Health US, LLC. Bupropion hydrochloride is used as an antidepressant used to treat the major depressive disorder (MDD) and seasonal affective disorder (SAD). The granules now have a total of 50 ANDA approvals from the USFDA (48 final approvals and 2 preliminary approvals).
Two target prices for Granule stock for FY 2025. The first price target for Granule stock in FY 2025 will be Rs 670. And the second price target for granules in FY2025 will be around Rs 700.
| Year | Granules Share Price Target 2025 |
|---|---|
| First Target 2025 | Rs 670 |
| Second target 2025 | Rs 700 |
Also read:- Add-Shop E-Retail Share Price Target 2022, 2023, 2024, 2025, 2030
Granules Share Price Target 2030
Foreign subsidiary Granules Pharmaceuticals, Inc. (GPI), a wholly owned subsidiary of Granules India, has received Abbreviated New Drug Application (ANDA) approval from the US Food & Drug Administration (USFDA) for Prazosin Hydrochloride Capsules, USP 1mg, 2mg and 5mg. It is bioequivalent to the reference drug (RLD), Mini plus capsules 1Mg, 2Mg & 5Mg from Pfizer Inc. The product will soon be available for the US market. Granule now has a total of 46 ANDA approvals from the US FDA (44 final approvals and 2 preliminary approvals). The current annual market for Prazosin hydrochloride 1 mg, 2 mg, 5 mg strength in the US is approximately $54 million.
The target price of granules will be available by the end of the financial year 2030. The price of the first share of granules will be Rs 1300. And the second price target for Granules stock will be Rs 1400 by the end of the financial year 2030.
| Year | Granules Share Price Target 2030 |
|---|---|
| First Target 2030 | Rs 1300 |
| Second Target 2030 | Rs 1400 |
Also read:- Lloyds Steel Share Price Target 2022, 2023, 2024, 2025, 2030
Future Prospectus of Granules Share
- Granules plans to expand its renewable energy portfolio by acquiring existing projects and is also looking for new opportunities in the transmission and distribution sector.
- In the coming years, Granules needs to open up and offer its customers and clients more options to do the right thing and continue to help the company make more money annually without distraction.
Granules Share Price Target 2022, 2023, 2024, 2025, 2030 Table
| Year | Granules Share Price Target |
|---|---|
| First Target 2022 | Rs 380 |
| Second Target 2022 | Rs 400 |
| First Target 2023 | Rs 460 |
| Second Target 2023 | Rs 480 |
| First Target 2024 | Rs 550 |
| Second Target 2024 | Rs 570 |
| First Target 2025 | Rs 670 |
| Second Target 2025 | Rs 700 |
| First Target 2030 | Rs 1300 |
| Second Target 2030 | Rs 1400 |
Risk of Granules Share
- Granules need additional funding to realize its full potential across the industry, otherwise, Granule will not be able to provide benefits or returns to its investors for years to come.
- Granules have a very high debt to the company which needs to be reduced in the coming years or any sales or income they generate annually will be used to cover their debts.
Expert Views on Granules Share
With all the features related to Granules stock we can say that you should watch this stock for some time and I would say you need to wait some time before investing in Granules stock.
Granules Share Price Target F.A.Q.
– Where is Granules Headquarters located?
Granules headquarters are located in Hyderabad, India.
– Who is the current MD of Granules?
KVS Rama Rao is the current MD of Granules.
– Which business granules does it participate in?
Granules India is a manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (APIs) such as tablets, caplets, immediate-release drugs, formulation intermediates (PFIs), and finished doses (FDs).
Conclusion
I hope that after reading the article Granules Share Price Target 2022, 2023, 2024, 2025, 2030 you must have got a good idea of what kind of performance can be seen in the growth of the Company. If you still have any questions related to this article in your mind, then do not forget to tell me in the comment. Stay tuned to Market in India for important information about this type of stock in the stock market.
Also read:-
